Investors & Media

Webcast ImageWebcast
2017 Wells Fargo Healthcare Conference  (Live)
09/06/17 at 11:25 a.m. ET
2017 Wells Fargo Healthcare Conference
Wednesday, September 6, 2017 11:25 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
15th Annual Morgan Stanley Global Healthcare Conference  (Live)
09/13/17 at 2:10 p.m. ET
15th Annual Morgan Stanley Global Healthcare Conference
Wednesday, September 13, 2017 2:10 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
Recent Press ReleasesMore >>
DateTitle
08/17/17Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Aug. 17, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Southern California Investor Conference on Thursday, August 24, 2017 in Newport Beach, CA; 2017 Wells Fargo Healthcare Conference on Wednesday, September 6, 2017 in Boston, MA; and 15th Annual Morgan Stanley Global Healthcare Conference on Wednesda... 
08/11/17Ionis to Independently Advance Inotersen and IONIS-FB-L Rx
Inotersen on Track for Marketing Authorization Filings This Year Conference Call Webcast Friday, August 11, 8:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif., Aug. 11, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today reported that the Company has retained all rights to inotersen and IONIS-FB-LRx. As part of a reprioritization of its pipeline and strategic review of its Rare Diseases business, GSK declined its options on both drugs. Ionis plans to file ... 
08/08/17Akcea Reports Financial Results and Highlights for Second Quarter 2017
Marketing authorization application submitted to the European Medicines Agency for the approval of volanesorsen Cash balance of approximately $300 million to fund volanesorsen launch and cardiometabolic pipeline advancement Strategic investment of $75 million by Novartis and Ionis   CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with ... 
08/08/17Ionis Provides Improved 2017 Guidance Following Strong Financial Performance
Conference Call Webcast Tuesday, August 8, 11:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif., Aug. 8, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today reported improved financial results with an operating loss of $1.7 million and operating income of $12.3 million for the three and six months ended June 30, 2017, respectively, compared to an operating loss of $48.9 million and $103.6 million for the same periods last year, all on a GAAP basis. Ionis also reported pro f... 
Upcoming EventsMore >>
DateTitle
08/24/17 10:00 a.m. PT
Southern California Investor Conference
Supporting Materials
09/06/17 11:25 a.m. ET
2017 Wells Fargo Healthcare Conference
Supporting Materials
09/13/17 2:10 p.m. ET
15th Annual Morgan Stanley Global Healthcare Conference
Supporting Materials

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.